Fractyl Health (GUTS) Stock Analysis & Winston Score
Fractyl Health is a small biotech company focused on treating type 2 diabetes and metabolic diseases. Its main product is Revita, a minimally invasive procedure that uses heat to resurface the lining of the small intestine, aiming to improve how the body controls blood sugar. The company targets patients with type 2 diabetes and works with hospitals and physicians in the healthcare system. Fractyl Health makes money by developing and eventually selling its medical procedure and related technology, though it is still in the clinical trial stage and has not yet generated meaningful revenue. The company is based in the United States and is very small, with a market cap around $100 million. Because it has no approved product yet, it burns through cash while funding research, which is the central risk — it must prove Revita works well enough to win regulatory approval before it runs out of money to operate.
Winston Score: 0/100 — Insufficient Data
Not enough data to score this stock reliably.
- Quality: Weak (0/30)
- Growth: Weak (2/20)
- Cash Flow: Data not available (0/10)
- Stability: Weak (1/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $0.81
Market Cap: $58M
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ

